Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-16), Viatris's 6-1 Month Momentum % is 7.27%.
The industry rank for Viatris's 6-1 Month Momentum % or its related term are showing as below:
XSWX:VTRS's 6-1 Month Momentum % is ranked better than 72.58% of 1032
companies
in the Drug Manufacturers industry
Industry Median: -10.53
vs XSWX:VTRS: 7.27
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Viatris 6-1 Month Momentum % Related Terms
XSWX:VTRS vs UTHR, NBIX, ELAN: 6-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris 6-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Viatris's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (XSWX:VTRS) has a 6-1 Month Momentum % of 7.27% as of Aug. 16, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Viatris and its competitors. According to the industry distribution chart, Viatris ranks #283 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 27.4%.
Is Viatris' 6-1 Month Momentum % too high?
Viatris' current 6-1 Month Momentum % is 7.27%. Based on the distribution chart, Viatris ranks #283 out of 1032 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Viatris has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' 6-1 Month Momentum % compare to UTHR and NBIX?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #283 out of 1032 companies for 6-1 Month Momentum %. This puts Viatris in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Drug Manufacturers company?
A good 6-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Viatris and its competitors. Viatris's current 6-1 Month Momentum % is 7.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current 6-1 Month Momentum % of 7.27%. The stock's GF Value™ is CHF9.27, compared to a current price of CHF13.19 — trading 42.3% above its estimated fair value. The current 6-1 Month Momentum % is 7.27%. Viatris' overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current 6-1 Month Momentum % is 7.27% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (XSWX:VTRS) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of CHF13.19 is trading 42.3% above its estimated GF Value™ of CHF9.27.
Key valuation signals for XSWX:VTRS:
6-1 Month Momentum %: 7.27%
GF Value™: CHF9.27 vs. price of CHF13.19 (42.3% above fair value)
No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
63GF Score
Get the complete analysis for XSWX:VTRS
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:VTRS has been successfully added to your 
